NCT03122496 - Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

June 3, 2022

Study Completion Date

June 3, 2022

Conditions

Metastatic Anaplastic Thyroid Cancer

Interventions

DRUG

durvalumab

Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.

DRUG

tremelimumab

Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.

RADIATION

Stereotactic Body Radiotherapy (SBRT)

SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab

Trial Locations (8)

Memorial Sloan Kettering Cancer Center, New York

Memoral Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Nassau, Uniondale

Memorial Sloan Kettering @ Rockville, Rockville Centre

Memorial Sloan Kettering Commack, Commack

Memoral Sloan Kettering Basking Ridge, Basking Ridge

Memoral Sloan Kettering Monmouth, Middletown

Memorial Sloan Kettering Bergen, Montvale